- Home
- CATO vs ACET Comparison
CATO vs ACET Comparison
Compare CATO & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATO | ACET |
|---|---|---|
| Founded | 1946 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 69.6M |
| IPO Year | 1994 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CATO | ACET |
|---|---|---|
| Price | $3.10 | $7.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $65.33 |
| AVG Volume (30 Days) | 51.0K | ★ 161.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.09 | ★ 59.82 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $649,806,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.36 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.19 | $0.45 |
| 52 Week High | $4.92 | $9.05 |
Technical Indicators
Market Signals| Indicator | CATO | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 57.76 |
| Support Level | $2.80 | $7.70 |
| Resistance Level | $3.22 | $8.46 |
| Average True Range (ATR) | 0.18 | 0.46 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 40.38 | 96.30 |
Price Performance
Historical ComparisonAbout CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.